Roopa Industries

how big is Roopa Industries?

As of Jun 06, Roopa Industries Ltd has a market capitalization of 50.00 Cr, with recent net sales of 120.68 Cr and a net profit of 2.03 Cr over the last four quarters. Shareholder's funds are 15.47 Cr, and total assets amount to 64.68 Cr as of Mar'24.

Market Cap: As of Jun 06, Roopa Industries Ltd has a market capitalization of 50.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 120.68 Cr. The sum of Net Profit for the same period is 2.03 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending Mar'24. The Shareholder's Funds are reported at 15.47 Cr, while the Total Assets amount to 64.68 Cr.

Who are in the management team of Roopa Industries?

As of March 2022, the management team of Roopa Industries includes T G Raghavendra (Chairman & Managing Director), V J Sarma (Whole-time Director), and three Non-Executive & Independent Directors: O Mohan Rao, A Satyanarayana Murthy, and Karunasree.

As of March 2022, the management team of Roopa Industries includes the following individuals:<BR><BR>1. T G Raghavendra - Chairman & Managing Director<BR>2. V J Sarma - Whole-time Director<BR>3. O Mohan Rao - Non-Executive & Independent Director<BR>4. A Satyanarayana Murthy - Non-Executive & Independent Director<BR>5. Karunasree - Non-Executive & Independent Director<BR><BR>These members play various roles in the governance and strategic direction of the company.

What does Roopa Industries do?

Roopa Industries Ltd is a micro-cap manufacturer and exporter of pharmaceuticals and biotechnology products, incorporated in 1985. As of March 2025, it reported net sales of 30 Cr and a market cap of Rs 49 Cr.

Overview: <BR>Roopa Industries Ltd is a manufacturer and exporter of pharmaceuticals and biotechnology products, operating within the micro-cap market segment.<BR><BR>History: <BR>The company was incorporated in 1985 and has evolved to manufacture and market bulk drugs and intermediaries. As of the latest quarterly results for March 2025, the company reported net sales and net profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 30 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 49 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 25.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.38 <BR>Return on Equity: 12.42% <BR>Price to Book: 3.10 <BR><BR>Contact Details: <BR>Address: 17/745 Alur Road, Kurnool District ADONI Andhra Pradesh : 518301 <BR>Fax: 91-40-23310379 <BR>Email: info@roopaindustries.com <BR>Website: http://www.roopaindustries.com

Has Roopa Industries declared dividend?

No Dividend History Available

Who are the peers of the Roopa Industries?

Roopa Industries' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Medi Caps, Dipna Pharmachem, Sandu Pharma, and Transchem. Roopa Industries has below average management and capital structure risks, with a 1-year return of 26.35%.

Peers: The peers of Roopa Industries are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Medi Caps, Dipna Pharmachem, Sandu Pharma., and Transchem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Medi Caps and Transchem. Below Average management risk is present at Roopa Industries, Sandu Pharma., and Mono Pharmacare. Growth is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted at Roopa Industries and Mono Pharmacare. Below Average growth is seen at Divi's Lab., Torrent Pharma, Medi Caps, Sandu Pharma., and Transchem, and the rest have growth ratings that do not qualify. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Medi Caps and Sandu Pharma. Below Average capital structure is present at Roopa Industries, Torrent Pharma, Dipna Pharmachem, and Transchem.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dipna Pharmachem at 169.36%, while the lowest is Medi Caps at -10.80%. Roopa Industries has a 1-year return of 26.35%, which is significantly higher than Medi Caps but lower than Dipna Pharmachem. Additionally, the six-month return is negative for Medi Caps, Sandu Pharma., and Transchem.

What is the technical trend for Roopa Industries?

As of June 4, 2025, Roopa Industries shows a neutral trend with a slight bullish bias, indicated by mixed signals from the MACD and daily moving averages, while weekly indicators suggest upward momentum.

As of 4 June 2025, the technical trend for Roopa Industries has changed from mildly bearish to sideways. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both the weekly and monthly time frames, suggesting some upward momentum. However, the daily moving averages are mildly bearish, which adds a cautionary note. The KST and Dow Theory are both mildly bullish on the weekly and monthly charts, reinforcing some positive sentiment. Overall, the current stance is neutral with a slight bullish bias, driven primarily by the weekly indicators.

Who are the top shareholders of the Roopa Industries?

The top shareholders of Roopa Industries are Star Niochem Pvt Limited with 18.91%, followed by public shareholder Sangeetha S at 9.51%. Individual investors own 40.95%, and there is one foreign institutional investor with a 0.25% stake, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Roopa Industries include Star Niochem Pvt Limited, which holds the largest stake at 18.91%. Following that, the highest public shareholder is Sangeetha S, with a holding of 9.51%. Additionally, individual investors collectively own 40.95% of the company. There is also one foreign institutional investor (FII) with a 0.25% stake. Notably, there are no pledged promoter holdings or mutual funds involved in this company.

Are Roopa Industries latest results good or bad?

Roopa Industries' latest results show strong net sales growth of 17.57% to Rs 35.07 crore, but a concerning 33.33% decline in net profit and a 'Strong Sell' rating from analysts suggest mixed overall performance, raising investor caution.

Roopa Industries' latest financial results present a mixed picture. On one hand, the company achieved its highest net sales in the last five quarters, reaching Rs 35.07 crore, which reflects a positive trend in revenue growth with a 17.57% increase compared to the previous quarter. This indicates the company's ability to maintain a stable revenue stream despite market challenges.<BR><BR>However, the standalone net profit saw a significant decline of 33.33%, which raises concerns about profitability. Additionally, the stock has received a 'Strong Sell' rating from MarketsMOJO, suggesting that analysts are wary of the company's future performance.<BR><BR>In summary, while the sales figures are encouraging, the drop in net profit and the negative analyst sentiment indicate that the overall results may not be viewed positively by investors. Stakeholders will likely be keeping a close eye on how Roopa Industries navigates its challenges in the competitive pharmaceuticals and biotechnology sector.

When is the next results date for Roopa Industries?

Roopa Industries will announce its results on 14 November 2025.

Roopa Industries will declare its results on 14 November 2025.

Is Roopa Industries overvalued or undervalued?

As of November 10, 2025, Roopa Industries is considered undervalued with a favorable PE Ratio of 18.65 and strong growth potential, making it a compelling investment opportunity compared to its peers, despite recent stock performance lagging behind the Sensex.

As of 10 November 2025, Roopa Industries has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE Ratio of 18.65, an EV to EBITDA of 14.98, and a PEG Ratio of 0.75, indicating strong potential for growth relative to its price.<BR><BR>In comparison to peers, Roopa Industries shows a more favorable valuation than Sun Pharma, which has a PE Ratio of 35.15 and is deemed expensive, as well as Divi's Lab, which is classified as very expensive with a PE Ratio of 71.55. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -33.75% compared to the Sensex's 6.91%, the overall valuation metrics suggest that Roopa Industries presents a compelling investment opportunity.

How has been the historical performance of Roopa Industries?

Roopa Industries has shown significant growth in net sales, increasing from 26.58 Cr in Mar'21 to 120.69 Cr in Mar'25, with profits also rising, despite a sharp increase in raw material costs. Operating profit reached 6.41 Cr in Mar'25, and profit after tax rose to 2.03 Cr, while total assets and liabilities grew to 76.46 Cr each.

Answer:<BR>The historical performance of Roopa Industries shows significant growth in net sales and profit over the years.<BR><BR>Breakdown:<BR>Roopa Industries has demonstrated a strong upward trend in net sales, increasing from 26.58 Cr in Mar'21 to 120.69 Cr in Mar'25, with a notable jump from 70.43 Cr in Mar'24. The total operating income followed a similar trajectory, reaching 120.69 Cr in Mar'25, up from 70.43 Cr in the previous year. However, raw material costs surged to 114.42 Cr in Mar'25, reflecting a substantial increase from 47.06 Cr in Mar'24. Despite this, the operating profit (PBDIT) rose to 6.41 Cr in Mar'25, compared to 5.68 Cr in Mar'24, indicating improved operational efficiency. Profit before tax also increased to 2.72 Cr in Mar'25 from 2.17 Cr in Mar'24, leading to a profit after tax of 2.03 Cr in Mar'25, up from 1.52 Cr in the prior year. The company's total assets grew to 76.46 Cr in Mar'25, while total liabilities also increased to 76.46 Cr, reflecting a balanced growth. The cash flow from operating activities showed a decline to -6.00 Cr in Mar'25, contrasting with a positive cash flow of 2.00 Cr in Mar'24, but the overall cash position improved with closing cash and cash equivalents rising to 3.00 Cr in Mar'25 from 2.00 Cr in Mar'24.

Should I buy, sell or hold Roopa Industries?

Which are the latest news on Roopa Industries?

Why is Roopa Industries Ltd falling/rising?

As of 03-Feb, Roopa Industries Ltd's stock price is rising to Rs 48.00, up 6.67%, driven by strong performance relative to its sector and increased investor interest. The stock has shown consistent gains, outperforming the Sensex and reflecting positive market sentiment.

As of 03-Feb, Roopa Industries Ltd's stock price is rising, currently at Rs 48.00, reflecting an increase of Rs 3.0 or 6.67%. This upward movement can be attributed to several factors. The stock has outperformed its sector by 3.88% today and has shown a consecutive gain over the last two days, accumulating a total return of 8.4% in this period. Notably, the stock opened with a significant gain of 15.56% today and reached an intraday high of Rs 52.<BR><BR>Additionally, the stock's performance over the past week has been strong, with a return of 7.87%, compared to a modest 2.30% gain in the Sensex. Year-to-date, Roopa Industries Ltd has also performed well, with an increase of 8.99%, while the Sensex has declined by 1.74%. The rising investor participation is evident, as the delivery volume on 02 Feb increased by 214.08% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>Despite some volatility, with an intraday range of Rs 7.99 and a volatility of 8.31%, the overall sentiment appears positive, supported by the stock's higher performance relative to its moving averages over shorter periods. The positive action in the Pharmaceuticals & Drugs sector, which gained 2.78%, may also contribute to the favorable conditions for Roopa Industries Ltd.